High interstitial fluid pressure - an obstacle in cancer therapy.
Many solid tumours show an increased interstitial fluid pressure (IFP), which forms a barrier to transcapillary transport. This barrier is an obstacle in tumour treatment, as it results in inefficient uptake of therapeutic agents. There are a number of factors that contribute to increased IFP in the tumour, such as vessel abnormalities, fibrosis and contraction of the interstitial matrix. Lowering the tumour IFP with specific signal-transduction antagonists might be a useful approach to improving anticancer drug efficacy.
Heldin
Carl-Henrik
CH
Ludwig Institute for Cancer Research, Box 595, SE-751 24 Uppsala, Sweden. C-H.Heldin@licr.uu.se
Rubin
Kristofer
K
Pietras
Kristian
K
Ostman
Arne
A
D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics*; D001692:Biological Transport; D001920:Bradykinin / Q000037:antagonists & inhibitors; D045604:Extracellular Fluid / Q000502:physiology*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000494:pharmacology; D006874:Hydrostatic Pressure; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000503:physiopathology*; D009536:Niacinamide / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D010982:Platelet-Derived Growth Factor; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D006821:Hyaluronoglucosaminidase; D000527:Alprostadil; D001920:Bradykinin